Literature DB >> 24202705

NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis.

Sarah L McLaughlin1, Ryan J Ice, Anuradha Rajulapati, Polina Y Kozyulina, Ryan H Livengood, Varvara K Kozyreva, Yuriy V Loskutov, Mark V Culp, Scott A Weed, Alexey V Ivanov, Elena N Pugacheva.   

Abstract

UNLABELLED: The scaffolding protein NEDD9 is an established prometastatic marker in several cancers. Nevertheless, the molecular mechanisms of NEDD9-driven metastasis in cancers remain ill-defined. Here, using a comprehensive breast cancer tissue microarray, it was shown that increased levels of NEDD9 protein significantly correlated with the transition from carcinoma in situ to invasive carcinoma. Similarly, it was shown that NEDD9 overexpression is a hallmark of highly invasive breast cancer cells. Moreover, NEDD9 expression is crucial for the protease-dependent mesenchymal invasion of cancer cells at the primary site but not at the metastatic site. Depletion of NEDD9 is sufficient to suppress invasion of tumor cells in vitro and in vivo, leading to decreased circulating tumor cells and lung metastases in xenograft models. Mechanistically, NEDD9 localized to invasive pseudopods and was required for local matrix degradation. Depletion of NEDD9 impaired invasion of cancer cells through inactivation of membrane-bound matrix metalloproteinase MMP14 by excess TIMP2 on the cell surface. Inactivation of MMP14 is accompanied by reduced collagenolytic activity of soluble metalloproteinases MMP2 and MMP9. Reexpression of NEDD9 is sufficient to restore the activity of MMP14 and the invasive properties of breast cancer cells in vitro and in vivo. Collectively, these findings uncover critical steps in NEDD9-dependent invasion of breast cancer cells. IMPLICATIONS: This study provides a mechanistic basis for potential therapeutic interventions to prevent metastasis. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24202705      PMCID: PMC3946989          DOI: 10.1158/1541-7786.MCR-13-0300

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  40 in total

1.  Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation.

Authors:  Inmaculada Ayala; Massimiliano Baldassarre; Giada Giacchetti; Giusi Caldieri; Stefano Tetè; Alberto Luini; Roberto Buccione
Journal:  J Cell Sci       Date:  2008-01-15       Impact factor: 5.285

2.  Noninvasive bioluminescence imaging in small animals.

Authors:  Kurt R Zinn; Tandra R Chaudhuri; April Adams Szafran; Darrell O'Quinn; Casey Weaver; Kari Dugger; Dale Lamar; Robert A Kesterson; Xiangdong Wang; Stuart J Frank
Journal:  ILAR J       Date:  2008

3.  MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression.

Authors:  N E Sounni; L Devy; A Hajitou; F Frankenne; C Munaut; C Gilles; C Deroanne; E W Thompson; J M Foidart; A Noel
Journal:  FASEB J       Date:  2002-04       Impact factor: 5.191

4.  Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells.

Authors:  Emma T Bowden; Ena Onikoyi; Rebecca Slack; Akira Myoui; Toshiyuki Yoneda; Kenneth M Yamada; Susette C Mueller
Journal:  Exp Cell Res       Date:  2006-01-25       Impact factor: 3.905

5.  Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation.

Authors:  S Hernandez-Barrantes; M Toth; M M Bernardo; M Yurkova; D C Gervasi; Y Raz; Q A Sang; R Fridman
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

6.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

7.  A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.

Authors:  J L Little; V Serzhanova; E Izumchenko; B L Egleston; E Parise; A J Klein-Szanto; G Loudon; M Shubina; S Seo; M Kurokawa; M F Ochs; E A Golemis
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

8.  Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells.

Authors:  K Shofuda; K Moriyama; A Nishihashi; S Higashi; H Mizushima; H Yasumitsu; K Miki; H Sato; M Seiki; K Miyazaki
Journal:  J Biochem       Date:  1998-08       Impact factor: 3.387

9.  NEDD9 promotes oncogenic signaling in mammary tumor development.

Authors:  Eugene Izumchenko; Mahendra K Singh; Olga V Plotnikova; Nadezhda Tikhmyanova; Joy L Little; Ilya G Serebriiskii; Sachiko Seo; Mineo Kurokawa; Brian L Egleston; Andres Klein-Szanto; Elena N Pugacheva; Richard R Hardy; Marina Wolfson; Denise C Connolly; Erica A Golemis
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

10.  NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer.

Authors:  Chenfei Kong; Changqing Wang; Liping Wang; Musong Ma; Chunbo Niu; Xiaoqian Sun; Juan Du; Zhixiong Dong; Shan Zhu; Jun Lu; Baiqu Huang
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

View more
  18 in total

1.  Prometastatic NEDD9 Regulates Individual Cell Migration via Caveolin-1-Dependent Trafficking of Integrins.

Authors:  Polina Y Kozyulina; Yuriy V Loskutov; Varvara K Kozyreva; Anuradha Rajulapati; Ryan J Ice; Brandon C Jones; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2014-10-15       Impact factor: 5.852

Review 2.  Digging a little deeper: the stages of invadopodium formation and maturation.

Authors:  Brian T Beaty; John Condeelis
Journal:  Eur J Cell Biol       Date:  2014-07-21       Impact factor: 4.492

Review 3.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

4.  High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.

Authors:  Mei Li; Shumei Yan; Muyan Cai; Jiabin Lu; Meifang Zhang; Ping Yang; Rongzhen Luo
Journal:  Mol Clin Oncol       Date:  2015-12-11

5.  Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.

Authors:  Brandon C Jones; Laura C Kelley; Yuriy V Loskutov; Kristina M Marinak; Varvara K Kozyreva; Matthew B Smolkin; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2017-02-24       Impact factor: 5.852

Review 6.  CAS proteins in health and disease: an update.

Authors:  Anna S Nikonova; Anna V Gaponova; Alexander E Kudinov; Erica A Golemis
Journal:  IUBMB Life       Date:  2014-06-24       Impact factor: 3.885

Review 7.  Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk.

Authors:  Michael S Shawky; Carmela Ricciardelli; Megan Lord; John Whitelock; Vito Ferro; Kara Britt; Erik W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-12       Impact factor: 2.673

8.  Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer.

Authors:  Zhong Chen; Xun Lan; Dayong Wu; Benjamin Sunkel; Zhenqing Ye; Jiaoti Huang; Zhihua Liu; Steven K Clinton; Victor X Jin; Qianben Wang
Journal:  Nat Commun       Date:  2015-09-16       Impact factor: 14.919

9.  Schwann cells promote prevascularization and osteogenesis of tissue-engineered bone via bone marrow mesenchymal stem cell-derived endothelial cells.

Authors:  Xinxin Zhang; Xiaorui Jiang; Shan Jiang; Xiyu Cai; Shengji Yu; Guoxian Pei
Journal:  Stem Cell Res Ther       Date:  2021-07-07       Impact factor: 6.832

10.  NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer.

Authors:  Y V Loskutov; P Y Kozyulina; V K Kozyreva; R J Ice; B C Jones; T J Roston; M B Smolkin; A V Ivanov; R B Wysolmerski; E N Pugacheva
Journal:  Oncogene       Date:  2014-09-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.